Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck Partners With Two Drug Consortia

by Ann M. Thayer
December 20, 2010 | A version of this story appeared in Volume 88, Issue 51

Merck & Co. has joined with the PATH Malaria Vaccine Initiative and New York University’s Langone Medical Center to develop a vaccine to prevent malaria infection. They will evaluate a peptide-protein conjugate approach to blocking the parasite’s circumsporozoite surface protein and thwarting its invasion of the human liver. Separately, Merck will work with BioPontis Alliance, an investment and scientific development firm that has created a drug discovery consortium with seven major university partners. Merck will provide its expertise to help align R&D with market needs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.